Abstract
Objective To study kinetics and associations between inflammation related proteins in circulation after pediatric allogenic hematopoietic stem cell transplantation (HSCT) to reveal proteomic signatures or individual soluble proteins associated with specific complications post HSCT.
Methods We used a proteomics method called Proximity Extension Assay to repeatedly measure 180 different proteins together with clinical variables, cellular immune reconstitution, and blood viral copy numbers in 27 children aged 1-18 years during a two-year follow up after allogenic HSCT. Protein profile analysis was done using unsupervised hierarchical clustering and a regression-based method, while Bonferroni-corrected Mann-Whitney U test was used for time point specific comparison of individual proteins against outcome.
Results At 6 months after allogenic HSCT, we could identify a protein profile pattern associated with occurrence of the complications chronic graft-versus-host disease, viral infections, relapse, and death. When protein markers were analyzed separately, the plasma concentration of the inhibitory and cytotoxic T cell surface protein FCRL6 (Fc receptor-like 6) was higher in patients with CMV viremia (log2-fold change 1.5 (p0.00099), 2.5 (p=0.00035) and 2.2 (p=0.045) at time points 6, 12 and 24 months). Flow cytometry confirmed that FCRL6 expression was higher in innate-like γδ T cells, indicating that these cells have a role in controlling CMV reactivation in HSCT recipients.
Conclusions The potentially druggable FCRL6 receptor on cytotoxic T cells appears to have a role in controlling CMV viremia post-HSCT. Our results suggest that system level analysis is a useful addition to the studying of single biomarkers in allogeneic HSCT.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AA reports funding from Finska Lakaresallskapet and Lastentautien Tutkimussaatio. MSV reports funding from the Academy of Finland (grant number 322123). EK reports funding from Lastentautien tutkimussaatio; University of Helsinki research funds and Helsinki University Hospital Governmental Funding for Research. LLE reports funding from the European Research Council ERC (677943); European Union Horizon 2020 research and innovation programme (955321); Academy of Finland (310561; 314443; 329278; 335434; 335611 and 341342); Sigrid Juselius Foundation; Biocenter Finland and ELIXIR Finland. XH and PH report no competing financial interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the Helsinki University Hospital (permit number: HUS/2306/2016) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Sharing Statement: Study protocols and analysis tools will be shared upon reasonable request via email to the corresponding author. Due to the European Union’s General Data Protection Regulation (2016/679) we cannot share individual patient data. As stated in the manuscript, part of the cohort data have been published before (Alexandersson, A. et al. Viral infections and immune reconstitution interaction after pediatric allogenic hematopoietic stem cell transplantation. Infect. Dis. 51, 772-778 (2019)).
Authorship Contributions: AA applied for ethics committee approval, collected patient data, planned analyses and wrote the manuscript. MV performed statistical analyses, made the figures and wrote the manuscript. NH performed flow cytometry analysis and wrote the manuscript. XH performed flow cytometry analysis and wrote the manuscript. MT planned the cohort and wrote the manuscript. PH collected patient data and wrote the manuscript. LE supervised and controlled the statistical analyses and wrote the manuscript. MK planned the cohort, acquired funding and wrote the manuscript. EK planned the experiments, supervised the project, acquired funding and wrote the manuscript.
Disclosure of conflict of interest: AA reports funding from the foundations Finska Läkaresällskapet and Lastentautien Tutkimussäätiö. MSV reports funding from the Academy of Finland (grant number 322123). EK reports funding from Lastentautien tutkimussäätiö, University of Helsinki research funds and Helsinki University Hospital Governmental Funding for Research. LLE reports funding from the European Research Council ERC (677943), European Union’s Horizon 2020 research and innovation programme (955321), Academy of Finland (310561, 314443, 329278, 335434, 335611 and 341342), and Sigrid Juselius Foundation. LLE’s research is also supported by Biocenter Finland, and ELIXIR Finland. NH, XH and PH report no competing financial interests.
Discussion revised
Data Availability
All data produced in the present study are available upon reasonable request to the authors
